The provision of made-to-order drugs ("specials") in primary care is expensive, often unnecessary, and associated with legal pitfalls, says the Drug and Therapeutics Bulletin (DTB).
It calls for a major overhaul of the practice, in a review of the evidence in this month's issue.
Bespoke drugs or "specials" are medicines made specifically to meet the needs of individual patients, so may be prepared in formulations and strengths which differ from those of standard licensed medicines.